Cargando…

Development of a Novel Severe Triple Allergen Asthma Model in Mice Which Is Resistant to Dexamethasone and Partially Resistant to TLR7 and TLR9 Agonist Treatment

Severe asthma is characterised by persistent inflammation, hyperreactivity and remodeling of the airways. No efficient treatment is available, this is particularly the case for steroid resistant phenotypes. Our aim therefore was to develop a preclinical model showing characteristics of severe human...

Descripción completa

Detalles Bibliográficos
Autores principales: Duechs, Matthias J., Tilp, Cornelia, Tomsic, Christopher, Gantner, Florian, Erb, Klaus J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949744/
https://www.ncbi.nlm.nih.gov/pubmed/24618687
http://dx.doi.org/10.1371/journal.pone.0091223
_version_ 1782306932160200704
author Duechs, Matthias J.
Tilp, Cornelia
Tomsic, Christopher
Gantner, Florian
Erb, Klaus J.
author_facet Duechs, Matthias J.
Tilp, Cornelia
Tomsic, Christopher
Gantner, Florian
Erb, Klaus J.
author_sort Duechs, Matthias J.
collection PubMed
description Severe asthma is characterised by persistent inflammation, hyperreactivity and remodeling of the airways. No efficient treatment is available, this is particularly the case for steroid resistant phenotypes. Our aim therefore was to develop a preclinical model showing characteristics of severe human asthma including steroid insensitivity. Mice were first sensitized with ovalbumin, extracts of cockroach or house dust mite followed by a challenge period of seven weeks. Further to this, an additional group of mice was sensitized with all three allergens and then challenged with allergen alternating weekly between allergens. All three allergens applied separately to the mice induced comparably strong Th2-type airway inflammation, airway hyperreactivity and airway remodeling, which was characterised by fibrosis and increased smooth muscle thickness. In contrast, application of all three allergens together resulted in a greater Th2 response and increased airway hyperreactivity and a stronger albeit not significant remodeling phenotype compared to using HDM or CRA. In this triple allergen model dexamethasone application, during the last 4 weeks of challenge, showed no suppressive effects on any of these parameters in this model. In contrast, both TLR7 agonist resiquimod and TLR9 agonist CpG-ODN reduced allergen-specific IgE, eosinophils, and collagen I in the lungs. The TLR9 agonist also reduced IL-4 and IL-5 whilst increasing IFN-γ and strongly IL-10 levels in the lungs, effects not seen with the TLR7 agonist. However, neither TLR agonist had any effect on airway hyperreactivity and airway smooth muscle mass. In conclusion we have developed a severe asthma model, which is steroid resistant and only partially sensitive to TLR7 and TLR9 agonist treatment. This model may be particular useful to test new potential therapeutics aiming at treating steroid resistant asthma in humans and investigating the underlying mechanisms responsible for steroid insensitivity.
format Online
Article
Text
id pubmed-3949744
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39497442014-03-12 Development of a Novel Severe Triple Allergen Asthma Model in Mice Which Is Resistant to Dexamethasone and Partially Resistant to TLR7 and TLR9 Agonist Treatment Duechs, Matthias J. Tilp, Cornelia Tomsic, Christopher Gantner, Florian Erb, Klaus J. PLoS One Research Article Severe asthma is characterised by persistent inflammation, hyperreactivity and remodeling of the airways. No efficient treatment is available, this is particularly the case for steroid resistant phenotypes. Our aim therefore was to develop a preclinical model showing characteristics of severe human asthma including steroid insensitivity. Mice were first sensitized with ovalbumin, extracts of cockroach or house dust mite followed by a challenge period of seven weeks. Further to this, an additional group of mice was sensitized with all three allergens and then challenged with allergen alternating weekly between allergens. All three allergens applied separately to the mice induced comparably strong Th2-type airway inflammation, airway hyperreactivity and airway remodeling, which was characterised by fibrosis and increased smooth muscle thickness. In contrast, application of all three allergens together resulted in a greater Th2 response and increased airway hyperreactivity and a stronger albeit not significant remodeling phenotype compared to using HDM or CRA. In this triple allergen model dexamethasone application, during the last 4 weeks of challenge, showed no suppressive effects on any of these parameters in this model. In contrast, both TLR7 agonist resiquimod and TLR9 agonist CpG-ODN reduced allergen-specific IgE, eosinophils, and collagen I in the lungs. The TLR9 agonist also reduced IL-4 and IL-5 whilst increasing IFN-γ and strongly IL-10 levels in the lungs, effects not seen with the TLR7 agonist. However, neither TLR agonist had any effect on airway hyperreactivity and airway smooth muscle mass. In conclusion we have developed a severe asthma model, which is steroid resistant and only partially sensitive to TLR7 and TLR9 agonist treatment. This model may be particular useful to test new potential therapeutics aiming at treating steroid resistant asthma in humans and investigating the underlying mechanisms responsible for steroid insensitivity. Public Library of Science 2014-03-11 /pmc/articles/PMC3949744/ /pubmed/24618687 http://dx.doi.org/10.1371/journal.pone.0091223 Text en © 2014 Duechs et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Duechs, Matthias J.
Tilp, Cornelia
Tomsic, Christopher
Gantner, Florian
Erb, Klaus J.
Development of a Novel Severe Triple Allergen Asthma Model in Mice Which Is Resistant to Dexamethasone and Partially Resistant to TLR7 and TLR9 Agonist Treatment
title Development of a Novel Severe Triple Allergen Asthma Model in Mice Which Is Resistant to Dexamethasone and Partially Resistant to TLR7 and TLR9 Agonist Treatment
title_full Development of a Novel Severe Triple Allergen Asthma Model in Mice Which Is Resistant to Dexamethasone and Partially Resistant to TLR7 and TLR9 Agonist Treatment
title_fullStr Development of a Novel Severe Triple Allergen Asthma Model in Mice Which Is Resistant to Dexamethasone and Partially Resistant to TLR7 and TLR9 Agonist Treatment
title_full_unstemmed Development of a Novel Severe Triple Allergen Asthma Model in Mice Which Is Resistant to Dexamethasone and Partially Resistant to TLR7 and TLR9 Agonist Treatment
title_short Development of a Novel Severe Triple Allergen Asthma Model in Mice Which Is Resistant to Dexamethasone and Partially Resistant to TLR7 and TLR9 Agonist Treatment
title_sort development of a novel severe triple allergen asthma model in mice which is resistant to dexamethasone and partially resistant to tlr7 and tlr9 agonist treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949744/
https://www.ncbi.nlm.nih.gov/pubmed/24618687
http://dx.doi.org/10.1371/journal.pone.0091223
work_keys_str_mv AT duechsmatthiasj developmentofanovelseveretripleallergenasthmamodelinmicewhichisresistanttodexamethasoneandpartiallyresistanttotlr7andtlr9agonisttreatment
AT tilpcornelia developmentofanovelseveretripleallergenasthmamodelinmicewhichisresistanttodexamethasoneandpartiallyresistanttotlr7andtlr9agonisttreatment
AT tomsicchristopher developmentofanovelseveretripleallergenasthmamodelinmicewhichisresistanttodexamethasoneandpartiallyresistanttotlr7andtlr9agonisttreatment
AT gantnerflorian developmentofanovelseveretripleallergenasthmamodelinmicewhichisresistanttodexamethasoneandpartiallyresistanttotlr7andtlr9agonisttreatment
AT erbklausj developmentofanovelseveretripleallergenasthmamodelinmicewhichisresistanttodexamethasoneandpartiallyresistanttotlr7andtlr9agonisttreatment